Material
Th17 cells are central to the pathogenesis of autoimmune disease, and recently specific noncoding microRNAs have been shown to regulate their development. However, it remains unclear whether microRNAs are also involved in modulating Th17 cell effector functions. Consequently, we examined the role of miR-155 in differentiated Th17 cells during their induction of experimental autoimmune encephalomyelitis. Using adoptive transfer experiments, we found that highly purified, myelin oligodendrocyte glycoprotein Ag-specific Th17 cells lacking miR-155 were defective in their capacity to cause experimental autoimmune encephalomyelitis. Gene expression profiling of purified miR-155 2/2 IL-17F + Th17 cells identified a subset of effector genes that are dependent on miR-155 for their proper expression through a mechanism involving repression of the transcription factor Ets1. Among the genes reduced in the absence of miR-155 was IL-23R, resulting in miR-155 2/2 Th17 cells being hyporesponsive to IL-23. Taken together, our study demonstrates a critical role for miR-155 in Th17 cells as they unleash autoimmune inflammation and finds that this occurs through a signaling network involving miR-155, Ets1, and the clinically relevant IL-23-IL-23R pathway. The Journal of Immunology, 2013, 190: 000-000.
A utoimmunity occurs when dysregulated, autoreactive immune cells inappropriately respond to self-Ags and cause unwarranted inflammation that is destructive to sophisticated tissue systems (1) . Recently, Th17 cells, a subset of CD4 + T cells defined by their expression of IL-17 cytokines, have emerged as key drivers of tissue inflammation. Th17 cells promote both the onset and persistence of inflammatory responses during autoimmune disorders including multiple sclerosis, arthritis, psoriasis, lupus, and inflammatory bowel disease (2, 3) .
Because of their central roles in driving disease, significant effort has gone into understanding the genes and pathways that regulate Th17 cell development. Skewing of naive CD4 + T cells toward the Th17 lineage is driven by the cytokines IL-6 and TGF-b, which induce Th17 cell signature genes through such factors as Stat3, RORgt, Ahr, Batf, and Irf4 (4) (5) (6) (7) (8) (9) (10) (11) (12) . Furthermore, differentiated Th17 cells must receive additional signals from cytokines such as IL-23 to expand and achieve full inflammatory potential in vivo (13) (14) (15) (16) (17) . Recently, noncoding microRNAs (miRNAs) have also been found to regulate Th17 cell development (18, 19) . However, how miRNAs fit into the known regulatory circuits underlying Th17 cell biology remains an important area of investigation.
miRNAs are small, ssRNA molecules that negatively regulate target gene expression posttranscriptionally. Specific miRNAs have been shown to support proper development of immune cells in mammals and have just recently been implicated in autoimmunity (20, 21) . Among the miRNAs expressed in immune cells is miR-155, which modulates the development of various inflammatory T cell subsets, including Th1, Th17, and regulatory T cells (18, (22) (23) (24) (25) (26) . Demonstrating its importance during inflammation in vivo, we and others have recently shown that miR-155 2/2 mice are highly resistant to distinct mouse models of autoimmunity, including experimental autoimmune encephalomyelitis (EAE)-a model of human multiple sclerosis, T cell-dependent colitis, and collagen-induced arthritis (18, 24, 27) . Furthermore, dysregulated expression of miR-155 is also observed in mice and people with various types of autoimmune disorders (24, (28) (29) (30) . Although these reports reveal a prominent, clinically relevant role for miR-155 during autoimmunity, they have not determined whether this is a consequence of reduced inflammatory T cell numbers or compromised effector cell function. Furthermore, it remains unclear how miR-155 functions at the molecular level to instruct Th17 cell biology.
In the current study, we have investigated the role of miR-155 in differentiated Th17 cells. This was accomplished by generating a novel mouse strain that allows for the isolation and analysis of viable, miR-155 2/2 IL-17F-expressing CD4 + T cells that specifically recognize the myelin oligodendrocyte glycoprotein (MOG) (22, 37, 38) .
Mouse models of EAE
EAE was induced in mice as described previously (18) . Briefly, MOG peptide (BD Biosciences) was emulsified in CFA (100 mg/ml) and injected s.c. into the base of the mouse's tail. Pertussis toxin was injected i.p. into mice on days 0 and 2. Clinical symptoms of EAE were scored according to the following criteria: 0, no symptoms; 0.5, partially limp tail; 1, completely limp tail; 1.5, impaired righting reflex; 2, hind-limb paresis; 2.5, hind-limb paralysis; 3, forelimb weakness; 4, complete paralysis; and 5, death.
Cell culture and retrovirus infection
For Th17 cell skewing, CD4 + splenocytes were isolated by using a CD4 + T cell isolation kit (Miltenyi Biotec) per manufacturer's instruction. The CD4 + T cells were cultured in RPMI 1640 medium supplemented with plate-bound anti-CD3e (5 mg/ml), soluble anti-CD28 (2 mg/ml), IL-6 (50 ng/ml), and TGF-b (3 ng/ml) (BioLegend) for 72 h. For some experiments, anti-IL-4 (5 mg/ml) and anti-IFN-g Abs (5 mg/ml) were supplemented to increase the differentiation of Th17 cells, or IMDM was used instead of RPMI 1640 medium. For delivery of the control or Ets1 short hairpin RNA (shRNA)-expressing retrovirus or MIG-IL-23R (Addgene 24066) (39) retrovirus, CD4 + T cells were cultured in RPMI 1640 medium with antiCD3e and anti-CD28 for 24 h. The next day, cells were spin infected with retrovector-containing medium (2500 rpm, 30˚C) for 90 min and cultured in Th17-skewing conditions. The retrovirus was produced by transfecting 293T cells as described previously (40) . Infected cells were GFP + , whereas IL-17F + cells were RFP + during FACS analyses.
Intracellular staining and flow cytometry
For analyses of IL-17F-expressing RFP + Th17 cells, cells were stained with fluorophore-conjugated anti-CD4 Abs, followed by FACS analysis using a BD LSRFortessa machine and FlowJo software. To detect intracellular expression of IL-17A or IFN-g, splenocytes, lymph nodes, or brain cells (purified with Percoll) were isolated from mice and seeded in 96-well plates. Cells were treated with 750 ng/ml ionomycin, 50 ng/ml PMA (Calbiochem), and 1 ml/well of GolgiPlug (BD Biosciences) for 4-5 h at 37˚C. Cells were subsequently surface stained with fluorphore-conjugated CD4 and CD3e Abs, followed by permeabilization and fixation. After washing, cells were stained with fluorophore-conjugated IL-17A Ab 
Quantitative real-time PCR and microarray
To analyze the relative levels of mRNAs encoding BIC, IL-17F, IL-17A, IL-23R, IL-22, Ets1, IL-2 or L32, Sybrgreen-based quantitative real-time PCR (qPCR) was conducted with the LightCycler 480 PCR system (Roche) and gene-specific primers. Primer sequences are available upon request. For all experiments, mRNA was normalized to L32.
For the microarray analysis, CD4 + T cells were purified from both miR-155 +/+ and miR-155 2/2 IL-17F RFP +/2 mouse spleens and cultured in vitro with Th17-skewing conditions. CD4 + RFP + and CD4 + RFP 2 cells were sorted for both genotypes. Total RNA was isolated using the RNeasy kit (Qiagen). Global mRNA levels were assayed using the SurePrint G3 Mouse GE 8 3 60K Microarray Kit (Agilent), which was carried out by the University of Utah core facility (https://bioserver.hci.utah.edu/ microarrayweb/ordering.html). The data were analyzed further using Genesifter and Ingenuity software. All data have been deposited into the National Center for Biotechnology Information Gene Expression Omnibus database under accession number GSE45122 (http://www.ncbi.nlm. nih.gov/geo/).
ELISAs
ELISAs to detect expression of IL-17A and IFN-g were performed with cytokine-specific kits (eBioscience), according to the manufacturer's instructions.
Immunoblotting
Cell pellets were lysed in 8 M urea buffer. Protein extracts were subjected to gel electrophoresis and transferred onto a nitrocellulose membrane, followed by Ab staining (Ets1 and b-actin; Santa Cruz Biotechnology) and detection as described previously (40) . Expression levels were quantified using National Institutes of Health ImageJ software.
Luciferase reporter assays
A region of the 39-untranslated region (39-UTR) of mouse Ets1 containing the conserved miR-155 binding site was cloned downstream from luciferase in the pmiReport plasmid. Site-directed mutagenesis was used to disrupt the seed sequence. The forward and reverse primer sequences for cloning Ets1 are 59-gtaactagtTACCCGAAACATGGAAGACTC-39 and 59-gttaagcttTGCACAGCATGGCTAGGA-39, respectively. The restriction enzyme sites are in lowercase. Luciferase assays were carried out as described previously (40) . In brief, 293T cells were transfected with combinations of a miR-155 expression plasmid, a luciferase expression construct with a 39-UTR, and a b-galactosidase expressing plasmid for normalization.
Statistical analysis
Statistical significance was determined by performing a Student two-tailed t test. A p value , 0.05 was considered significant. For the ingenuity transcription factor analysis, the z-score is calculated by the Ingenuity Pathway Analysis software and represents the confidence that a transcription factor is activated or repressed based on the consistency between the direction of change of known targets of the transcription regulator from the microarray data set and what is expected from literature.
Results

Generation and characterization of miR-155
2/2 IL-17F RFP reporter mice
To investigate the role of miR-155 in Th17 cell function and to circumvent the limitations of using intracellular staining to identify Th17 cells, we developed a mouse strain where miR-155 2/2 Th17 cells are marked with the RFP under the control of the IL-17F locus (Fig. 1A) . IL-17F RFP reporter mice have been described previously and shown to faithfully mark Th17 cells both in vitro and in vivo (38 (Fig. 1C, 1D ). Defective IL-17F RFP expression in the absence of miR-155 also occurred when cells were cultured in IMDM, which is a medium rich in aromatic amino acids that promotes higher levels of Th17 cell differentiation by Wt CD4 + T cells compared with more conventional RPMI 1640 medium (Fig. 1C, 1D) Fig. 2A) . Global gene expression profiling was performed using a microarray analysis. Genes differentially regulated by miR-155 in purified IL-17F + Th17 cells were identified, and this subset contained several genes involved in T cell-lineage skewing and Th17 cell effector functions (Supplemental Table I ).
Next, we used Ingenuity software to mine our microarray results and uncover canonical pathways most impacted by miR-155. This approach identified Th cell differentiation as the most significant biological pathway impacted by miR-155, and altered B and T cell signaling in rheumatoid arthritis as the second most effected process. Both of these are consistent with a critical role for miR-155 in Th17 cell biology during autoimmunity.
Many of these pathway differences are represented by the expression of specific IL genes, which are either elevated or decreased in miR-155 2/2 IL-17F + Th17 cells (Fig. 2B ). Within this gene subset, we detected several that have been linked to Th17 cell biology, including IL-17A, IL-17F, IL-23R, and IL-22, that were decreased in miR-155 2/2 IL-17F + Th17 cells compared with miR-155 +/+ controls. Alternatively, cytokines representing other Th lineages, such as IL-4, IL-5, and IL-13, were increased in miR-155 2/2 IL-17F + Th17 cells (Fig. 2B) . qPCR was performed to validate these defects in Th17-related genes expression profiles observed in miR-155 2/2 IL-17F + Th17 cells and among those assayed were IL-17A, IL-17F, IL-23R, and IL-22 (Fig. 2C , Supplemental Fig. 1 ). We also assessed RORgT mRNA levels and found minimal differences between the groups (Fig 2C) . These data demonstrate that miR-155 is not only important for the development of IL-17F-expressing cells but also critical for the expression of Th17 cell effector genes in differentiated, IL-17F-expressing Th17 cells.
miR-155 directly targets Ets1 in IL-17F + Th17 cells
We next sought to identify mRNA targets of miR-155 with relevance to Th17 cell biology. To systematically search for potential miR-155 targets, we further analyzed our microarray data from were identified (Fig. 3A) . Because miR-155 inhibits expression of its targets, those transcription factors with a predicted increase in their levels in miR-155 2/2 cells were of interest (Fig. 3A, red line). On this list were several factors containing a conserved miR-155 binding site in their 39-UTRs, according to Targetscan software, and these include Ets1, AP1 (cFos), C/EBPb, and cMAF. Among these, our attention was drawn to Ets1 for several reasons: 1) Ets1 was the most likely transcription factor to be activated in miR-155 2/2 IL-17F + Th17 cells according to our analysis (Fig.  3A) ; 2) it has a highly conserved bonding site for miR-155 in its 39-UTR (Fig. 3B); and 3) it has an established function as an inhibitor of Th17 cells (42) .
To determine whether miR-155 directly targets mouse Ets1, we cloned a region of the Ets1 39-UTR containing the conserved miR-155 binding site downstream from luciferase and performed luciferase assays using 293T cells. Results indicated that miR-155 overexpression repressed luciferase in an Ets1 39-UTR-dependent manner (Fig. 3C) (Fig. 3D ).
Taken together, these results identify Ets1 as a direct target of miR-155 in Th17 cells.
Ets1 is a functionally relevant target of miR-155 in IL-17F + Th17 cells
Following the identification of Ets1 as a direct target of miR-155 during Th17 development, we next determined whether reducing its levels would impact expression of Th17-related genes in miR-155 2/2 CD4 + Th17 cells. To accomplish this, we built a retroviral vector that expresses an Ets1 shRNA based on a format that we have described previously (43) . Using two different Ets1 shRNAs or a control vector, we transduced miR-155
CD4
+ T cells and assayed the expression of Ets1 and Th17-related genes under Th17 cell-skewing conditions (Fig. 4A) . Ets1 protein levels were re- duced in cells expressing the shRNA cassette when compared with the control vector (Fig. 4B) . Ets1 knockdown in miR-155
2/2
Th17 cells led to upregulation of several Th17-related genes, including IL-17A, IL-23R, and IL-22 (Fig. 4B) . Of note, Ets1 knockdown did not affect IL-17F expression.
To further define the role of Ets1 in purified Th17 cells, we took advantage of our IL-17F reporter system and sorted out RFP + (IL-17F (Fig. 4A) . Analysis of these RFP + GFP + cells by intracellular staining and FACS revealed defective expression of IL-17A in the absence of miR-155 compared with Wt controls, and this was statistically significant (Fig. 4C, 4D) . Notably, knockdown of Ets1 in miR-155 2/2 cells led to increased amounts of IL-17A + cells, albeit this did not reach control levels (Fig. 4C, 4D) . Moreover, Ets1 knockdown significantly increased the expression of other Th17-related genes in miR-155 2/2 RFP + GFP + cells, and these included IL-17A, IL-23R, and IL-22 (Fig. 4E) . Taken together, these results indicate that Ets1 is a functionally relevant target of miR-155 in Th17 cells.
miR-155 promotes the function of IL-17F + Th17 cells during EAE
To determine whether miR-155 is required for the functionality of differentiated IL-17F + Th17 cells, we generated miR-155 +/+ and miR-155 2/2 IL-17F RFP +/2 2d2 TCR Tg + mice (Fig. 5A ). The 2D2 TCR specifically recognizes the MOG peptide, and T cells expressing this TCR can elicit EAE in mice on a C57BL/6 genetic background (37) . By using this new mouse strain, we were able to isolate miR-155 +/+ or miR-155 2/2 IL-17F+ Th17 cells that specifically recognize MOG and test the importance of miR-155 during Th17 cell encephalogenic function in vivo (Fig. 5B) . We adoptively transferred 2 3 10 4 in vitro generated miR-155 (Fig. 5C, 5D ). We also analyzed the brains and spleens from both groups for the presence of transferred IL-17F + Th17 cells. Consistent with the reduced EAE symptoms, we observed significantly fewer miR-155 2/2 compared with miR-155 +/+ Vb11 + CD4 + T cells in the spleens and brains of mice immunized with MOG (Fig. 6A, 6B, 6E, 6F ). Intracellular staining of the recovered T cells revealed that miR-155 2/2 cell were defective in their expression of IL-17A (Fig. 6C,   6D , 6G, 6H). In addition, we also observed decreased IL-17A + GM-CSF + cells in brain with miR-155 2/2 cell transfer (Fig. 6H) .
It is also of note that there were still reduced EAE symptoms in the absence of miR-155 despite the TCR having a fixed specificity. These data demonstrate that miR-155 is required for both the development and proper function of IL-17F + Th17 cells during EAE (Supplemental Fig. 2 ).
miR-155 is necessary for proper IL-23 responsiveness by IL-17F + Th17 cells
The IL-23/IL-23R signaling pathway is critical for the expansion of Th17 cells in vivo and the induction of EAE in mice, and polymorphisms in the IL-23R gene have been linked to human autoimmunity (17, (31) (32) (33) (Fig. 7A, 7B ). These data indicate that miR-155 (Fig. 7G,  7H ). These data provide evidence that one important function of miR-155 during tissue inflammation is the promotion of IL-23R expression by IL-17F + Th17 cells.
Discussion
In this paper, we evaluated the role of miR-155 in developed Th17 cells and made several important discoveries. First, miR-155 is required for expression of several effector genes in differentiated IL-17F-expressing Th17 cells. Second, miR-155 directly targets the transcription factor Ets1, a known negative regulator of Th17 cell formation. Thus, elevated expression of Ets1 in miR-155 +/+ counterparts, and this phenotype is consistent with the defective expression of several effector genes including IL-23R. These results predict that inhibiting miR-155 could reduce Th17 cell function during human autoimmune disease.
The identification of Ets1 as a target of miR-155 in Th17 cells provides insight into the ability of miR-155 to regulate Th17 cell effector function. Ets1 is a well-established negative regulator of Th17 cell development, and also targeted by another miRNA involved in the formation of Th17 cells, called miR-326 (19, 42) . Thus, Ets1 appears to be a common target of miRNAs in the context of inflammatory Th17 cell biology. Ets1 is mutated in patients with certain types of autoimmune conditions, underscoring its connection to pathological tissue inflammation (44, 45) . Taken together, Ets1 is emerging as an important node in the cellular networks that regulate human autoimmunity, and its therapeutic manipulation should be examined as a possible treatment.
A previous study found that Ets1 functions downstream of IL-2 to block expression of Th17-related genes (42) . Coculture experiments and exogenous IL-2 delivery demonstrated that Ets1 regulates the responsiveness of CD4 + T cells to the inhibitory effects of IL-2 on Th17 cell development (which appeared in this study to be more relevant than its role in promoting IL-2 expression). The study did not detect Ets1 binding to the IL-17A gene promoter, or Ets1-dependent effects on Stat5 activation. Thus, the mechanisms by which Ets1 regulates IL-17A and other Th17 genes (such as IL-23R) in response to IL-2 are unclear. Our experiments were done without IL-2 blocking Abs or addition of exogenous IL-2. The only IL-2 in the system was produced by the activated T cells themselves, and we did not observe differences in the amount of IL-2 expressed by miR-155 2/2 versus Wt T cells (Supplemental Fig. 3) . Thus, the ∼2-fold increase in Ets1 in miR-155 2/2 cells is not sufficient to increase IL-2 expression in this context. Taken together with the study described above, it is possible that miR-155 functions to reduce the Ets1-dependent repressive effects of IL-2 signaling on Th17 cell effector gene expression. This will be an area of future investigation.
Our study also suggests that multiple targets of miR-155, in addition to Ets1, are relevant during Th17 cell development and likely targets multiple relevant mRNAs in this cellular compartment. Further experiments will be needed to test whether other targets predicted from our ingenuity analysis, or presently unidentified, are being regulated by miR-155 during Th17 cell development and/or function. In order for Th17 cells to expand during autoimmunity, they must be able to respond to IL-23 that is produced by a variety of immune cells within secondary lymphoid organs and lesions that are created during autoimmunity (31) . Certain genetic variants of the IL-23R gene that promote IL-23R function have been associated with human autoimmune disorders, including Crohn's disease and psoriasis, as determined through genome-wide association studies. This further highlights the relevance of this pathway during human autoimmunity (34) (35) (36) . Importantly, we found IL-23R to be among the effector genes that is regulated by the miR-155-Ets1 axis in Th17 cells, and provide evidence that miR-155 2/2 Th17 cells are unresponsive to IL-23 ex vivo. Furthermore, recovery of IL-23R expression by miR-155 2/2 Th17 cells partially restored EAE disease symptoms. The regulation of this signaling pathway by miR-155 is a promising component of miR-155 biology that has not been recognized previously, yet may turn out to be a central mechanism by which miR-155 promotes autoimmune inflammation.
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